论文部分内容阅读
目的研究血管内皮生长因子-C(VEGF-C)和细胞粘附因子(CD44v6)在非小细胞肺癌组织中的表达及其与淋巴血道转移和预后的关系。方法回顾分析56例术前未进行化疗和放疗的非小细胞肺癌的切除标本,采用免疫组化SP法检测肺癌组织中VEGF-C和CD44v6的表达,采用χ2检验分析其表达与肺癌生物学行为的关系,采用Kaplan-meier生存曲线及logrank方法检测生存率。结果鳞癌组织中VEGF-C、CD44v6的阳性表达率分别为65.63%(21/32)、56.25%(18/32),腺癌组织中分别为66.67%(16/24)、62.50%(15/24)。VEGF-C及CD44v6的阳性表达与肺癌淋巴结的转移、肺癌的病理分期关系密切(P<0.05),且与肺癌术后发生转移密切相关。VEGF-C、CD44v6阳性表达者3及5年生存率分别为18.79%、7.24%和17.73%、11.04%,阴性表达者为66.23%、59.55%和68.26%、54.33%,两者之间差异显著(P<0.05);VEGF-C与CD44v6阳性表达呈显著正相关。结论联合检测VEGF-C和CD44v6表达对于非小细胞肺癌淋巴血行转移、病理分期、术后转移复发的评估有一定临床意义,可用于指导临床选择正确的综合治疗。
Objective To investigate the expression of vascular endothelial growth factor-C (VEGF-C) and cell adhesion molecule (CD44v6) in non-small cell lung cancer (NSCLC) and its relationship with lymphoid metastasis and prognosis. Methods Fifty-six resected specimens of non-small cell lung cancer without chemotherapy and radiotherapy were retrospectively analyzed. The expressions of VEGF-C and CD44v6 in lung cancer tissues were detected by immunohistochemical SP method. The expressions of VEGF-C and CD44v6 in lung cancer tissues were analyzed by χ2 test. The Kaplan-Meier survival curve and logrank method were used to detect the survival rate. Results The positive rates of VEGF-C and CD44v6 in squamous cell carcinoma were 65.63% (21/32) and 56.25% (18/32), respectively, and those in adenocarcinoma were 66.67% (16/24) and 62.50% /twenty four). The positive expression of VEGF-C and CD44v6 was closely related to lymph node metastasis and pathological stage of lung cancer (P <0.05), and was closely related to the metastasis of lung cancer. The 3-year and 5-year survival rates of VEGF-C and CD44v6 positive patients were 18.79%, 7.24% and 17.73%, 11.04% and 66.23%, 59.55% and 68.26% and 54.33% respectively, with a significant difference between the two (P <0.05). There was a significant positive correlation between the expression of VEGF-C and CD44v6. Conclusions The combined detection of VEGF-C and CD44v6 expression has clinical significance in the evaluation of lymphoid metastasis, pathological stage and postoperative metastasis and recurrence in non-small cell lung cancer and can be used to guide the clinical choice of the correct combination therapy.